Newsfiscal.ai
Citius Oncology Reports Fiscal Q4 2026 Preliminary LYMPHIR Sales Data
· Published
Article summary
Citius Pharmaceuticals' majority-owned subsidiary, Citius Oncology, reported preliminary, unaudited fiscal fourth-quarter 2026 sales data for its FDA-approved immunotherapy, LYMPHIR.
An excerpt from the original article.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…